Hepatitis B

News Hepatitis B

• Frost & Sullivan: Combination drugs are the future of the European Hepatitis B and C therapeutics markets

  The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market for more

• Study finds interferon, one of the body's proteins, induces persistent viral infection

  Scientists at The Scripps Research Institute (TSRI) have made a counterintuitive finding that may lead to new ways to clear persistent infection that is the hallmark of such diseases as AIDS, hepatitis B and hepatitis C. The study, reported in the journal Science, focused on the activity of the body more

• Expanding high risk population drives European hepatitis B and C diagnostics market, finds Frost & Sullivan

  In recent years, the prevalence of hepatitis C has increased among high risk sub-group populations, including immigrants from areas where the disease is endemic, injecting drug users (IDUs) and patients co-infected with HIV. “Overall, the incidence of hepatitis C among IDUs in Europe is estimated to more

Publications Hepatitis B

• Identification of a Novel Antimicrobial Peptide from Human Hepatitis B Virus Core Protein Arginine-Rich Domain (ARD)

  by Heng-Li Chen, Pei-Yi Su, Ya-Shu Chang, Szu-Yao Wu, You-Di Liao, Hui-Ming Yu, Tsai-Ling Lauderdale, Kaichih Chang, Chiaho Shih The rise of multidrug-resistant (MDR) pathogens causes an increasing challenge to public health. Antimicrobial peptides are considered a possible solution to this probl more

• Combination of DNA Prime – Adenovirus Boost Immunization with Entecavir Elicits Sustained Control of Chronic Hepatitis B in the Woodchuck Model

  by Anna D. Kosinska, Ejuan Zhang, Lena Johrden, Jia Liu, Pia L. Seiz, Xiaoyong Zhang, Zhiyong Ma, Thekla Kemper, Melanie Fiedler, Dieter Glebe, Oliver Wildner, Ulf Dittmer, Mengji Lu, Michael Roggendorf A potent therapeutic T-cell vaccine may be an alternative treatment of chronic hepatitis B vir more

• Full genome ultra‐deep pyrosequencing associates G‐to‐A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B

  Summary Human APOBEC3 (A3) cytosine deaminases are antiviral restriction factors capable of editing the genome the hepatitis B virus (HBV). Despite the importance of the human A3 protein family for the innate immune response little is known about the clinical relevance for hepatitis B. The aim more

Market studies Hepatitis B

• Indonesia Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: The government’s aim to create proper universal healthcare coverage is unlikely to be realised in the short term but would create investors’ interest in the country. We highlight some of the beneficiaries such as local generic drug manufacturers and medical devices suppliers. Given the co more

• Medivir AB (MVIR B) - Financial and Strategic SWOT Analysis Review

  Medivir AB (Medivir) is a pharmaceuticals company. It undertakes the research and development of drugs for high-value treatments of infectious diseases. The company operates through two business segments, namely, Pharmaceuticals segment and Parallel Import segment. The Pharmaceuticals segment compri more

• Israel Pharmaceuticals and Healthcare Report Q4 2012

  BMI View: Although Israel claims its very efficient healthcare system means it does not need to spend as much of its GDP on provision (some 7.6% was spent on this purpose in 2011), in reality the government's fiscal austerity and sick funds traditionally keep the most expensive innovative drugs and more

Websites Hepatitis B